Gene: BRAF ×
Source: BEFREE ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
BRAF
0.770 GeneticVariation BEFREE Finally, rafoxanide had anti-proliferation effect on both wild type and B-Raf V600E mutated MM cells. 30583070

2019
dbSNP: rs113488022
rs113488022
BRAF
0.770 GeneticVariation BEFREE Previous studies in Western countries demonstrated BRAF V600E mutation only in a small subset of multiple myeloma (MM) patients. 29807803

2018
dbSNP: rs113488022
rs113488022
BRAF
0.770 GeneticVariation BEFREE Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation. 27641727

2017
dbSNP: rs113488022
rs113488022
BRAF
0.770 GeneticVariation BEFREE We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chronic lymphocytic leukemias/small lymphocytic lymphomas (CLLs/SLLs), and 21 plasma cell neoplasms (PCNs) for BRAF V600E expression by IHC. 26071465

2015
dbSNP: rs113488022
rs113488022
BRAF
0.770 GeneticVariation BEFREE BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. 25794135

2015
dbSNP: rs113488022
rs113488022
BRAF
0.770 GeneticVariation BEFREE Targeting the BRAF V600E mutation in multiple myeloma. 23612012

2013
dbSNP: rs113488022
rs113488022
BRAF
0.770 GeneticVariation BEFREE While no RASSF1A or BRAF mutation (V599E) was detected in any of the primary MM studied (n = 21), the latter was found in the U266 cell line. 14616967

2003
dbSNP: rs397516896
rs397516896
BRAF
0.710 GeneticVariation BEFREE Interestingly, we detected a novel BRAF D594N mutation in one patient with multiple myeloma. 21910720

2011
dbSNP: rs121913377
rs121913377
BRAF
0.070 GeneticVariation BEFREE Finally, rafoxanide had anti-proliferation effect on both wild type and B-Raf V600E mutated MM cells. 30583070

2019
dbSNP: rs121913377
rs121913377
BRAF
0.070 GeneticVariation BEFREE Previous studies in Western countries demonstrated BRAF V600E mutation only in a small subset of multiple myeloma (MM) patients. 29807803

2018
dbSNP: rs121913377
rs121913377
BRAF
0.070 GeneticVariation BEFREE Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation. 27641727

2017
dbSNP: rs121913377
rs121913377
BRAF
0.070 GeneticVariation BEFREE BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. 25794135

2015
dbSNP: rs121913377
rs121913377
BRAF
0.070 GeneticVariation BEFREE We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chronic lymphocytic leukemias/small lymphocytic lymphomas (CLLs/SLLs), and 21 plasma cell neoplasms (PCNs) for BRAF V600E expression by IHC. 26071465

2015
dbSNP: rs121913377
rs121913377
BRAF
0.070 GeneticVariation BEFREE Targeting the BRAF V600E mutation in multiple myeloma. 23612012

2013
dbSNP: rs121913377
rs121913377
BRAF
0.070 GeneticVariation BEFREE While no RASSF1A or BRAF mutation (V599E) was detected in any of the primary MM studied (n = 21), the latter was found in the U266 cell line. 14616967

2003
dbSNP: rs1057519718
rs1057519718
BRAF
0.010 GeneticVariation BEFREE Interestingly, we detected a novel BRAF D594N mutation in one patient with multiple myeloma. 21910720

2011